First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States

Antimicrob Agents Chemother. 2005 Aug;49(8):3538-40. doi: 10.1128/AAC.49.8.3538-3540.2005.

Abstract

Carbapenemases are rare in the United States. This is the first report of a United States nosocomial outbreak of pan-resistant Pseudomonas aeruginosa infections due to an integron-borne metallo-beta-lactamase, VIM-2. This emergence of carbapenemases on mobile genetic elements in the United States warrants surveillance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Bacterial Agents / pharmacology
  • Cross Infection / epidemiology*
  • Cross Infection / microbiology
  • Disease Outbreaks*
  • Humans
  • Integrons*
  • Male
  • Microbial Sensitivity Tests
  • Molecular Sequence Data
  • Pseudomonas Infections / epidemiology
  • Pseudomonas Infections / microbiology
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / enzymology*
  • Pseudomonas aeruginosa / genetics
  • Sequence Analysis, DNA
  • United States / epidemiology
  • beta-Lactam Resistance*
  • beta-Lactamases / biosynthesis*
  • beta-Lactamases / genetics

Substances

  • Anti-Bacterial Agents
  • beta-lactamase bla(vim-2)
  • beta-Lactamases

Associated data

  • GENBANK/AY943084